Knight Cancer signal achievements of 2022
People at the Knight Cancer Institute accomplished a lot in 2022. Through innovative, collaborative research and education, the institute delivers cancer prevention, detection, and care — one...
Tag: beat AML
A better roadmap for beating a deadly leukemia
Acute myeloid leukemia, or AML, is the most common acute blood cancer in adults — and one of the most difficult to treat. Scientists at Oregon Health & Science University have discovered a...
Study reveals inherited risk of leukemia
Inherited mutations that increase the risk of developing a dangerous blood cancer are more common than previously appreciated, a new study reveals. Researchers analyzed acute myeloid leukemia...
Beat AML study paves way for precision treatment
Using genetic information to match patients to targeted therapies may improve survival in people with a fast-moving leukemia. Because acute myeloid leukemia is such a fast-moving and deadly cancer,...
How a deadly leukemia develops resistance to one of the newest targeted therapies
OHSU Knight Cancer Institute scientists have identified key gene networks and signaling pathways that cancerous cells in acute myeloid leukemia use to resist treatment with the drug venetoclax, one...
Rapid precision medicine is feasible in fight against a formidable leukemia
The Beat AML clinical trial has matched 250 study participants to targeted treatments for acute myeloid leukemia – with promising early results. Regulators were wary of the complicated study...
An elaborate clinical trial aims a multitude of targeted therapies at one formidable cancer
A $10 million gift from The Harry T. Mangurian Jr. Foundation will help The Leukemia & Lymphoma Society expand the Beat AML Master Trial underway at the OHSU Knight Cancer Institute and other...
Fighting a formidable leukemia with an expansive clinical trial
The best available treatment for acute myeloid leukemia is a drug combination established more than 30 years ago. And today less than a third of newly diagnosed AML patients survive beyond five...
Overcoming the impasse in acute myeloid leukemia research
Nine drug companies and six universities have now joined an unusual collaboration to break the logjam in research on acute myeloid leukemia (AML), a blood cancer lacking effective treatments....